This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics. For Elrexfio® (elranatamab) Prescribing Information for United Kingdom click here. ELREXFIO® (elranatamab) has a conditional marketing authorisation. A conditional marketing authorisation means that further evidence of efficacy and safety data are being collected. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year. The licensing authority will review new information on this medicine at least every year and update the Summary of Product Characteristics as necessary.
Oncology services within NHS trusts continue to be overstretched by an influx of treatments which have prolonged survival rates and added to the capacity challenges faced by the NHS. ePROMs may offer a solution to help service providers manage these increasing patient numbers and workload demand.1
ePROMs are online questionnaires completed by patients to monitor any disease symptoms, adverse events of treatment, indicators of disease progression and physical function. They can offer a practical solution for patient support as part of a technology-enabled model of care.
For more information on how to integrate ePROMs within your NHS trust, please download the resources below. These resources provide guidance on the three key phases of integrating ePROMs into patient care:
These guides have been developed in collaboration with an NHS medical oncologist with extensive experience with ePROMs, Professor Galina Velikova from Leeds NHS THFT.
References
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.